12:00 AM
 | 
Apr 23, 2007
 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Syndax Pharmaceuticals Inc.

Waltham, Mass.

Technology: Histone deacetylase (HDAC) inhibitors in combination with nuclear receptor ligands

Disease focus: Cancer

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >